BiotechTube

Henagliflozin 10 mg daily + Metformin 1700 mg daily

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Metabolic Dysfunction-associated Steatotic Liver Disease

Conditions

Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus

Trial Timeline

Dec 31, 2024 → Dec 31, 2026

NCT ID
NCT06762223

About Henagliflozin 10 mg daily + Metformin 1700 mg daily

Henagliflozin 10 mg daily + Metformin 1700 mg daily is a approved stage product being developed by Jiangsu Hengrui Medicine for Metabolic Dysfunction-associated Steatotic Liver Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06762223. Target conditions include Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06762223ApprovedRecruiting

Competing Products

20 competing products in Metabolic Dysfunction-associated Steatotic Liver Disease

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
85
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
77
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
77
14C-labeled YM178Astellas PharmaPhase 1
33
TRC150094Torrent PharmaceuticalsPhase 1/2
41
LY518674Eli LillyPhase 2
52
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
77
Metformin + PlaceboEli LillyApproved
85
Tirzepatide + SemaglutideEli LillyPre-clinical
23
LY3849891 + PlaceboEli LillyPhase 1
33
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaApproved
85
AZD2693 + PlaceboAstraZenecaPhase 1
33
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
rosuvastatinAstraZenecaApproved
85
EfinopegdutideMerckPhase 2
52
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
52
Vericiguat + PlaceboMerckPhase 2
52
MetforminMerckPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85
Bupivacaine Liposome InjectionApproved
85